ArticleScientific reports2019

A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer.

Masahito Shimojo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.